Weston Daniel

Weston Daniel, PhD, is Chief Development Officer at EVOQ Therapeutics, where he leads the development of the company’s antigen-specific immune tolerance programs from preclinical development through clinical translation. He oversees scientific and development strategy across EVOQ’s NanoDisc platform, including CMC, nonclinical development, translational biomarkers, regulatory strategy, and clinical development. A major focus of his current work is advancing EVOQ’s celiac disease program toward first-in-human clinical evaluation while expanding the NanoDisc platform into additional autoimmune indications. Dr. Daniel has extensive experience in nanotechnology, nucleic acid, and biotechnology research and development, translational science, therapeutic development, and the design of programs intended to bridge mechanistic immunology with clinically meaningful endpoints. His work at EVOQ focuses on developing practical, scalable approaches to induce durable antigen-specific immune tolerance without generalized immunosuppression.